MA51134A - Anticorps anti-alpha-synucléine - Google Patents
Anticorps anti-alpha-synucléineInfo
- Publication number
- MA51134A MA51134A MA051134A MA51134A MA51134A MA 51134 A MA51134 A MA 51134A MA 051134 A MA051134 A MA 051134A MA 51134 A MA51134 A MA 51134A MA 51134 A MA51134 A MA 51134A
- Authority
- MA
- Morocco
- Prior art keywords
- alpha
- synuclein antibody
- synuclein
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1720970.1A GB201720970D0 (en) | 2017-12-15 | 2017-12-15 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51134A true MA51134A (fr) | 2021-03-24 |
Family
ID=61008785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051134A MA51134A (fr) | 2017-12-15 | 2018-12-13 | Anticorps anti-alpha-synucléine |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11292831B2 (fr) |
| EP (1) | EP3724228A1 (fr) |
| JP (1) | JP7326281B2 (fr) |
| KR (1) | KR102781727B1 (fr) |
| CN (1) | CN111655727B (fr) |
| AU (1) | AU2018382527B2 (fr) |
| BR (1) | BR112020010508A2 (fr) |
| CA (1) | CA3084106A1 (fr) |
| CL (1) | CL2020001607A1 (fr) |
| EA (1) | EA202091482A1 (fr) |
| EC (1) | ECSP20039610A (fr) |
| GB (1) | GB201720970D0 (fr) |
| IL (2) | IL303672B2 (fr) |
| MA (1) | MA51134A (fr) |
| MX (1) | MX2020005810A (fr) |
| MY (1) | MY203402A (fr) |
| PE (1) | PE20201062A1 (fr) |
| PH (1) | PH12020551006A1 (fr) |
| SG (1) | SG11202004740RA (fr) |
| TN (1) | TN2020000077A1 (fr) |
| TW (2) | TWI860014B (fr) |
| UA (1) | UA130114C2 (fr) |
| UY (1) | UY38012A (fr) |
| WO (1) | WO2019115671A1 (fr) |
| ZA (2) | ZA202003414B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3558363A1 (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Formulations d'anticorps anti-tnf alpha |
| CA3051839A1 (fr) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Anticorps anti-alpha-synucleine et leurs utilisations |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| AU2020350769A1 (en) * | 2019-09-20 | 2022-03-31 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| AU2020394842A1 (en) * | 2019-12-04 | 2022-06-30 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
| US12441877B2 (en) | 2020-08-07 | 2025-10-14 | Lg Chem, Ltd. | Thermoplastic resin composition |
| CN113912715B (zh) * | 2021-12-15 | 2022-03-01 | 北京凯祥弘康生物科技有限公司 | 一种抗α-突触核蛋白抗体及其相关产品和应用 |
| CN119233987B (zh) * | 2022-05-20 | 2025-08-29 | 长春金赛药业有限责任公司 | 抗α-Synuclein抗体及其用途 |
| CN115043927B (zh) * | 2022-06-17 | 2024-03-19 | 武汉大学 | 针对抗α-突触核蛋白K80Hcy抗体的抗原肽及其应用 |
| WO2025076635A1 (fr) * | 2023-10-12 | 2025-04-17 | Universite Laval | ANTICORPS ANTI-α-SYNUCLÉINE ET LEURS UTILISATIONS |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| WO2002050121A1 (fr) | 2000-12-13 | 2002-06-27 | Taisho Pharmaceutical Co.,Ltd. | Nouvel anticorps |
| WO2003045128A2 (fr) | 2001-11-21 | 2003-06-05 | New York University | Polypeptides immunogenes synthetiques ne formant pas de depots et peptides homologues destines a des repetitions amyloide $g(b), proteine prion, amyline, $g(a)-synucleine, ou polyglutamine pour induction d'une reponse immunitaire a ceux-ci |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8697082B2 (en) | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| SI1633189T1 (sl) | 2003-05-19 | 2017-12-29 | Prothena Biosciences Limited | Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc |
| WO2005047860A2 (fr) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Anticorps a l'alpha-synucleine |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| US20080300204A1 (en) | 2005-07-19 | 2008-12-04 | University Of Rochester | Alpha-Synuclein Antibodies and Methods Related Thereto |
| WO2007021255A1 (fr) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Anticorps de l’alpha-synucléine |
| PL3067066T3 (pl) * | 2007-02-23 | 2019-09-30 | Prothena Biosciences Limited | Zapobieganie i leczenie choroby synukleinopatycznej i amyloidogennej |
| JP5558834B2 (ja) | 2007-02-23 | 2014-07-23 | ヤンセン アルツハイマー イミュノセラピー | シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置 |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101289665A (zh) * | 2007-04-18 | 2008-10-22 | 复旦大学 | 一种建立抗帕金森病动物模型的方法 |
| SI2282758T1 (sl) | 2008-04-29 | 2019-03-29 | Bioarctic Ab | Protitelesa in vakcine za uporabo pri terapevtskih in diagnostičnih metodah za alfa-sinuklein-povezane motnje |
| CN102317316B (zh) | 2008-12-19 | 2014-08-13 | 帕尼玛制药股份公司 | 人抗α突触核蛋白自身抗体 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| LT2539366T (lt) | 2010-02-26 | 2018-04-25 | Bioarctic Ab | Protofibriles surišantys antikūnai ir jų panaudojimas parkinsono ligos, demencijos su levi kūneliais ir kitų alfa-sinukleinopatijų terapiniuose ir diagnostiniuose būduose |
| EP2366714A1 (fr) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Auto-anticorps d'origine naturelle contre l'alpha-synucléine qui inhibent l'agrégation et la cytotoxicité de l'alpha-synucléine |
| EP2635907A4 (fr) | 2010-11-05 | 2014-04-16 | Univ Brandeis | Alpha-synucléine clivée ice en tant que marqueur biologique |
| DE102011008153B4 (de) | 2011-01-08 | 2018-08-09 | Aj Roboscreen Gmbh | Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein |
| PT2723379T (pt) * | 2011-06-23 | 2018-11-14 | Univ Of Zuerich | Moléculas de ligação anti-alfa-sinucleína |
| WO2013063516A1 (fr) | 2011-10-28 | 2013-05-02 | Neotope Biosciences Limited | Anticorps humanisés qui reconnaissent l'alpha-synucléine |
| KR102246217B1 (ko) | 2012-01-27 | 2021-04-29 | 프로테나 바이오사이언시즈 리미티드 | 알파-시누클레인을 인식하는 인간화된 항체 |
| WO2013173827A2 (fr) | 2012-05-18 | 2013-11-21 | Board Of Regents Of The University Of Nebraska | Procédés et compositions pour inhiber des maladies du système nerveux central |
| ES2856272T3 (es) | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| WO2015051159A1 (fr) | 2013-10-02 | 2015-04-09 | The Rockefeller University | Anticorps de protofibrilles amyloïdes et leurs procédés d'utilisation |
| EP3071974A2 (fr) | 2013-11-19 | 2016-09-28 | Prothena Biosciences Limited | Suivi d'une immunothérapie de maladie à corps de lewy d'après des symptômes de constipation |
| WO2015075011A1 (fr) | 2013-11-21 | 2015-05-28 | F. Hoffmann-La Roche Ag | Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation |
| WO2015155694A1 (fr) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Navettes de la barrière hémato-encéphalique contenant des anticorps reconnaissant l'alpha-synucléine |
| US10155030B2 (en) | 2014-05-23 | 2018-12-18 | University Of South Florida | Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| SG11201701953RA (en) | 2014-09-11 | 2017-04-27 | Univ Texas | Detection of misfolded proteins |
| WO2016040903A1 (fr) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Détection de protéine bêta amyloïde à repliement incorrect |
| WO2016040905A1 (fr) | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Détection de protéine alpha-synucléine mal-repliée |
| WO2016061389A2 (fr) | 2014-10-16 | 2016-04-21 | Genentech, Inc. | Anticorps anti-alpha-synucléine et leurs méthodes d'utilisation |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| ES2890073T3 (es) | 2015-08-25 | 2022-01-17 | Prothena Biosciences Ltd | Métodos para detectar alfa-sinucleína fosforilada |
| AU2016361350B2 (en) | 2015-11-23 | 2023-04-06 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
| EP3440225A4 (fr) | 2016-04-06 | 2020-03-11 | Imago Pharmaceuticals, Inc. | Anticorps thérapeutiques pour le traitement de la neurodégénérescence |
| CA3025987A1 (fr) | 2016-06-02 | 2017-12-07 | Medimmune Limited | Anticorps anti-alpha-synucleine et leurs utilisations |
| GB201611840D0 (en) | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
| US20190194324A1 (en) | 2016-08-23 | 2019-06-27 | The Johns Hopkins University | THERAPEUTIC USES OF LAG3 THE (alpha)-SYNUCLEIN TRANSMISSION RECEPTOR |
| US10889635B2 (en) | 2016-11-15 | 2021-01-12 | H. Lundbeck A/S | Agents, uses and methods for the treatment of synucleinopathy |
| US20180134776A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (4H6) |
| US20180134775A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (7A11) |
| US20180134777A1 (en) | 2016-11-17 | 2018-05-17 | United Arab Emirates University | Alpha-Synuclein Antibodies (11D12) |
| AU2017376670A1 (en) | 2016-12-12 | 2019-07-18 | The Michael J. Fox Foundation For Parkinson's Research | Antibodies to human alpha-synuclein |
| EP3555127B1 (fr) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, utilisations et procédés |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| AU2018206279B2 (en) | 2017-01-06 | 2020-09-03 | Abl Bio Inc. | Anti-alpha-syn antibody and use thereof |
| JP2020504151A (ja) | 2017-01-09 | 2020-02-06 | カリフォルニア インスティチュート オブ テクノロジー | パーキンソン病の診断および治療薬における腸内微生物叢の使用 |
| CA3051839A1 (fr) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Anticorps anti-alpha-synucleine et leurs utilisations |
| JOP20190227A1 (ar) | 2017-03-31 | 2019-09-30 | Biogen Int Neuroscience Gmbh | تركيبات وطرق لعلاج اعتلالات السينوكلين |
| IL270612B2 (en) | 2017-05-16 | 2025-02-01 | Amprion Inc | Discovery of misfolded tau protein |
| WO2018237338A1 (fr) | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anticorps anti-alpha-synucléine et leurs procédés d'utilisation |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
-
2017
- 2017-12-15 GB GBGB1720970.1A patent/GB201720970D0/en not_active Ceased
-
2018
- 2018-12-13 MA MA051134A patent/MA51134A/fr unknown
- 2018-12-13 SG SG11202004740RA patent/SG11202004740RA/en unknown
- 2018-12-13 JP JP2020532563A patent/JP7326281B2/ja active Active
- 2018-12-13 UA UAA202003350A patent/UA130114C2/uk unknown
- 2018-12-13 EA EA202091482A patent/EA202091482A1/ru unknown
- 2018-12-13 TN TNP/2020/000077A patent/TN2020000077A1/en unknown
- 2018-12-13 BR BR112020010508-2A patent/BR112020010508A2/pt unknown
- 2018-12-13 CA CA3084106A patent/CA3084106A1/fr active Pending
- 2018-12-13 WO PCT/EP2018/084689 patent/WO2019115671A1/fr not_active Ceased
- 2018-12-13 IL IL303672A patent/IL303672B2/en unknown
- 2018-12-13 US US16/772,043 patent/US11292831B2/en active Active
- 2018-12-13 KR KR1020207020006A patent/KR102781727B1/ko active Active
- 2018-12-13 CN CN201880080860.7A patent/CN111655727B/zh active Active
- 2018-12-13 MX MX2020005810A patent/MX2020005810A/es unknown
- 2018-12-13 IL IL275223A patent/IL275223B2/en unknown
- 2018-12-13 EP EP18829766.7A patent/EP3724228A1/fr active Pending
- 2018-12-13 PE PE2020000717A patent/PE20201062A1/es unknown
- 2018-12-13 AU AU2018382527A patent/AU2018382527B2/en active Active
- 2018-12-13 MY MYPI2020002764A patent/MY203402A/en unknown
- 2018-12-14 UY UY0001038012A patent/UY38012A/es not_active Application Discontinuation
- 2018-12-14 TW TW112129007A patent/TWI860014B/zh active
- 2018-12-14 TW TW107145231A patent/TWI806940B/zh active
-
2020
- 2020-06-08 ZA ZA2020/03414A patent/ZA202003414B/en unknown
- 2020-06-14 PH PH12020551006A patent/PH12020551006A1/en unknown
- 2020-06-15 CL CL2020001607A patent/CL2020001607A1/es unknown
- 2020-07-14 EC ECSENADI202039610A patent/ECSP20039610A/es unknown
-
2021
- 2021-09-01 ZA ZA2021/06370A patent/ZA202106370B/en unknown
-
2022
- 2022-02-28 US US17/682,082 patent/US12410244B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47694A (fr) | Anticorps anti-tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| EP3903817A4 (fr) | Nouvel anticorps anti-ccr8 | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA53434A (fr) | Anticorps anti-tigit | |
| EP3498840A4 (fr) | Anticorps anti-lag-3 | |
| EP3423089A4 (fr) | Anticorps anti-tigit | |
| FR25C1022I1 (fr) | Anticorps anti-pd-1 | |
| EP3883970A4 (fr) | Anticorps anti-b7-h3 | |
| EP3334757A4 (fr) | Anticorps anti-tigit | |
| EP3297671A4 (fr) | Anticorps anti-ror1 | |
| MA46041A (fr) | Anticorps anti-tim -3 | |
| MA50352A (fr) | Anticorps multispécifiques | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA49749A (fr) | Anticorps anti-cd137 | |
| MA44236A (fr) | Anticorps anti-tgfbêta 2 | |
| EP3617231A4 (fr) | Anticorps anti-gpc-1 | |
| EP3492591A4 (fr) | Anticorps anti-b7-h4 | |
| EP3526247A4 (fr) | Anticorps anti-il1-rap | |
| MA51134A (fr) | Anticorps anti-alpha-synucléine | |
| EP3399992A4 (fr) | Anticorps autoréticulants | |
| EP3383915A4 (fr) | Anticorps anti-pd-1 | |
| EP3484919A4 (fr) | Anticorps anti-bêta-amyloïde | |
| MA51135A (fr) | Anticorps anti-alpha-synucléine |